- Home
- IMA vs BCAB Comparison
IMA vs BCAB Comparison
Compare IMA & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMA | BCAB |
|---|---|---|
| Founded | 2019 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.4M | 71.6M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | IMA | BCAB |
|---|---|---|
| Price | $6.70 | $0.34 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $16.00 | $1.00 |
| AVG Volume (30 Days) | 48.2K | ★ 2.4M |
| Earning Date | 02-15-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $800,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.70 | $0.24 |
| 52 Week High | $18.00 | $1.43 |
Technical Indicators
Market Signals| Indicator | IMA | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 29.87 |
| Support Level | N/A | $0.29 |
| Resistance Level | N/A | $0.41 |
| Average True Range (ATR) | 0.00 | 0.09 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 0.00 | 6.38 |
Price Performance
Historical ComparisonAbout IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.